№ 4 / 2013 / 71-76

The experience of the non-invasive diagnosis of atrophic gastritis in current clinical practice

Author: Belkovets A.V.¹, Kurilovich S.A.², Reshetnikov O.V.³, Ragino J.I.⁴, Shcherbakova L.V.⁵

Abstract

Non-invasive diagnostics of atrophic gastritis as a main premalignant condition was carried out in 818 people which consistently applied to polyclinic on their` own or according to the physician recommendation. «GastroPanel» sets for enzyme-linked immunoassay (Biohit, Finland), which allow measuring pepsinogen I, pepsinogen II and gastrin 17, have been used. Experience of use of gastric atrophy biomarkers in the current clinical practice shows high frequency of detection of fundus and antral atrophy (totally not less than 40 % and the highest frequency – at the 50–69 years of age range).

Key words

GastroPanel, atrophic gastritis, gastrin-17, non-invasive diagnostics, pepsinogens, gastric cancer

References

1. Kurilovich S.A., Reshetnikov O.V., Krotov S.A. et al. Dyspeptic syndrome: from epidemiological studies to cancer prevention // Byulleten' Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk. 2006. (4). 74–79. (in Russian)

2. Kurilovich S.A., Reshetnikov O.V. Epidemiology of digestive diseases in Western Siberia. Novosibirsk, 2000. 75 p. (in Russian)

3. Pyrveeva K.V., Lapina T.L., Ivaschkin V.T. et al. Value of serum pepsinogens and gastrin-17 in the diagnostic of atrophic gastritis // Rossiyskiy zhurnal gastroenterologii, gepatologii i coloproctologii. 2005. (5). 48–51. (in Russian)

4. Agréus L., Storskrubb T., Aro P. et al. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population // Scand. J. Gastroenterol. 2009. 44. 564–570.

5. Correa P., Haenszel W., Cuello C. et al. Gastric precancerous process in a high risk population: cohort follow-up // Cancer Res. 1990. 50. 4737–4740.

6. Di Mario F., Moussa A.M., Caruana P. et al. ‘Serological biopsy’ in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection // Scand. J. Gastroenterol. 2003. 38. 1223–1227.

7. Dinis-Ribeiro M., da Costa-Pereira A., Lopes C. et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma // Neoplasia. 2004. 6. 449–456.

8. Kuipers E.J., Uyterlinde A.M., Peña A.S. et al. Long-term sequelae of Helicobacter pylori gastritis // Lancet. 1995. 345. 1525–1528.

9. Miki K., Fujishiro M., Kodashima S., Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population // Dig. Endosc. 2009. 21. 78–81.

10. Pasechnikov V.D., Chukov S.Z., Kotelevets S.M. et al. Possibility of non-invasive diagnosis of gastric mucosal precancerous changes // World J. Gastroenterol. 2004. 10. 3146–3150.

11. Sande N., Nikulin M., Nilsson I. et al. Increased risk of developing atrophic gastritis in patients infected with CagA+ Helicobacter pylori // Scand. J. Gastroenterol. 2001. 36. 928–933.

12. Sipponen P., Kekki M., Haapakoski J. et al. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data // Int. J. Cancer. 1985. 35. 173–177.

13. Sipponen P., Vauhkonen M., Helske T. et al. Low circulating levels of gastrin-17 in patients with Barrett‘s esophagus // World J. Gastroenterol. 2005. 11. 5988–5992.

14. Sipponen P., Ranta P., Helske T. et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study // Scand. J. Gastroenterol. 2002. 37. 785–791.

15. Storskrubb T., Aro P., Ronkainen J. et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study // Scand. J. Gastroenterol. 2008. 43. 1448–1455.

16. Valle J., Valle J., Kekki M. et al. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study // Scand. J. Gastroenterol. 1996. 31. 546–550.

17. Väänänen H., Vauhkonen M., Helske T. et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study // Eur. J. Gastroenterol. Hepatol. 2003. 15. 885–891.

18. Yanaoka K., Oka M., Yoshimura N. et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels // Int. J. Cancer. 2008.123. 917–926.

About Authors (Correspondence):

Belkovets A.V. – candidate of medical sciences, researcher of laboratory of gastroenterology, e-mail: belkovets@gmx.de

Kurilovich S.A. – doctor of medical sciences, professor, head of laboratory of gastroenterology, head of gastroenterology course, e-mail: kurilovich@yandex.ru

Reshetnikov O.V. – doctor of medical sciences, leading researcher of laboratory of gastroenterology, e-mail: reshetnikov_ov@mail.ru

Ragino Yu.I. – doctor of medical sciences, professor, head of laboratory of clinical-population and preventive investigations of therapeutic and endocrine diseases, e-mail: ragino@mail.ru

Shcherbakova L.V. – leading researcher of laboratory of clinical-population and preventive researches of therapeutic and endocrine diseases, e-mail: sherbakova@iimed.ru

Full Text

11-4-2013.pdf

Received: 02/02/2015